In Brief: Tri-Point Medical
This article was originally published in The Gray Sheet
Executive Summary
Tri-Point Medical: Files premarket approval application with FDA for its TraumaSeal topical tissue cohesion product. TraumaSeal is intended as an alternative to surgical sutures or staples in closing wounds "caused by skin lacerations and incisions, minimally invasive surgery, and plastic surgery," Tri-Point says. The product has been granted expedited review status by FDA. In March, the Raleigh, North Carolina firm entered an exclusive worldwide marketing agreement for the product with Johnson & Johnson's Ethicon division ("The Gray Sheet" April 1, In Brief)...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.